Please login to the form below

Not currently logged in
Email:
Password:

Dr Edward Browne joins Sygnature Discovery

He becomes associate director of drug metabolism and pharmacokinetics

Sygnature Discovery Dr Edward BrowneNottingham, UK-based Sygnature Discovery has expanded its drug metabolism and pharmacokinetics (DMPK) team with the appointment of Dr Edward Browne as associate director.

Dr Browne (pictured right) moves to the drug discovery service provider from GlaxoSmithKline, where he most recently served as head of DMPK for its Singapore operations.

He first joined GSK as a bioanalytical scientist in 2000, before working at Simbec Research in a similar post.

In 2005, Dr Browne re-joined GSK, becoming a team leader in its neural pathways discovery performance unit in Singapore before taking on increasingly senior roles.

Dr Timothy Schulz-Utermoehl, director of DMPK at Sygnature Discovery, said: “I am delighted to welcome Ed to the team here at Sygnature.

“Ed brings significant DMPK and drug discovery experience to our rapidly expanding department as we continue to build our CNS expertise and large molecule bio analysis.”

24th October 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics